Download Files:
Sunvozertinib
$180 – $1,450
Products Details
Product Description
– Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52)[1].
Web ID
– HY-132842
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H35ClFN7O3
References
– [1]Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
CAS Number
– 2370013-12-8
Molecular Weight
– 584.08
Compound Purity
– 99.92
SMILES
– C=CC(NC1=C(N2C[C@@H](CC2)N(C)C)C=C(C(NC3=NC=CC(NC4=C(C=C(C(Cl)=C4)F)C(C)(O)C)=N3)=C1)OC)=O
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 80°C)
Target
– Btk;EGFR
Isoform
– EGFR/ErbB1/HER1;ErbB2/HER2
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
